中国临床药理学杂志
中國臨床藥理學雜誌
중국림상약이학잡지
The Chinese Journal of Clinical Pharmacology
2015年
22期
2199-2201
,共3页
陈青%卢敏%籍增洋%吴宇耀%黄翯
陳青%盧敏%籍增洋%吳宇耀%黃翯
진청%로민%적증양%오우요%황학
伏格列波糖%糖耐量减低%老年冠心病%干预
伏格列波糖%糖耐量減低%老年冠心病%榦預
복격렬파당%당내량감저%노년관심병%간예
voglibose%impaired glucose tolerance%elderly coronary heart disease%intervent
目的 评价伏格列波糖在合并糖耐量减低老年冠心病患者中的早期干预治疗效果. 方法 80例合并糖耐量减低老年冠心病患者分为对照组和试验组,各40例,对照组用阿卡波糖50 mg,每天3次,试验组口服伏格列波糖20 mg,每天3次,连续12个月. 比较2组疗效及空腹血糖( FPG)、2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、胰岛素 β细胞功能(HOMA -β)以及胰岛素抵抗指数(HOMA-IR)指标. 结果 试验组治疗后FPG、2 h PG、HbA1c、HOMA -β、HOMA-IR指标显著低于对照组( P<0.05). 试验组合并糖耐量降低发展为2型糖尿病发生率低于对照组;试验组转化为糖耐量正常百分比高于对照组,但差异均无统计学意义(P>0.05). 试验组不良反应发生率为10.0%,显著低于对照组的22.5%( P<0.05).结论 伏格列波糖对老年冠心病合并耐糖量减低患者早期干预疗效好,能够降低患者血糖,降低心血管疾病发生率.
目的 評價伏格列波糖在閤併糖耐量減低老年冠心病患者中的早期榦預治療效果. 方法 80例閤併糖耐量減低老年冠心病患者分為對照組和試驗組,各40例,對照組用阿卡波糖50 mg,每天3次,試驗組口服伏格列波糖20 mg,每天3次,連續12箇月. 比較2組療效及空腹血糖( FPG)、2 h血糖(2 h PG)、糖化血紅蛋白(HbA1c)、胰島素 β細胞功能(HOMA -β)以及胰島素牴抗指數(HOMA-IR)指標. 結果 試驗組治療後FPG、2 h PG、HbA1c、HOMA -β、HOMA-IR指標顯著低于對照組( P<0.05). 試驗組閤併糖耐量降低髮展為2型糖尿病髮生率低于對照組;試驗組轉化為糖耐量正常百分比高于對照組,但差異均無統計學意義(P>0.05). 試驗組不良反應髮生率為10.0%,顯著低于對照組的22.5%( P<0.05).結論 伏格列波糖對老年冠心病閤併耐糖量減低患者早期榦預療效好,能夠降低患者血糖,降低心血管疾病髮生率.
목적 평개복격렬파당재합병당내량감저노년관심병환자중적조기간예치료효과. 방법 80례합병당내량감저노년관심병환자분위대조조화시험조,각40례,대조조용아잡파당50 mg,매천3차,시험조구복복격렬파당20 mg,매천3차,련속12개월. 비교2조료효급공복혈당( FPG)、2 h혈당(2 h PG)、당화혈홍단백(HbA1c)、이도소 β세포공능(HOMA -β)이급이도소저항지수(HOMA-IR)지표. 결과 시험조치료후FPG、2 h PG、HbA1c、HOMA -β、HOMA-IR지표현저저우대조조( P<0.05). 시험조합병당내량강저발전위2형당뇨병발생솔저우대조조;시험조전화위당내량정상백분비고우대조조,단차이균무통계학의의(P>0.05). 시험조불량반응발생솔위10.0%,현저저우대조조적22.5%( P<0.05).결론 복격렬파당대노년관심병합병내당량감저환자조기간예료효호,능구강저환자혈당,강저심혈관질병발생솔.
Objective To investigate the effect of early intervention of voglibose on elderly patients with coronary heart disease and impaired glucose tolerance.Methods A total of 80 elderly patients with glucose tolerance impairation and coronary heart disease were divided into control group(n=40) and trial group(n=40).Control group was treated with acarbose, 50 mg, tid;the trial group was treated with voglibose, 20 mg, tid.The treatment lasted for 12 months.The efficacy and fasting blood glucose ( FPG ) , 2 h glucose ( 2 h PG ) , glycosylated hemoglobin ( HbA1c) , insulin resistance index ( HOMA-β) and insulin resistance index ( HOMA -IR ) were compared between the two groups. Results The FPG, 2 h PG, HbA1c, HOMA-βand HOMA -IR in the trial group were significantly lower than those in the control group ( P<0.05) , and the development of impaired glucose tolerance( IGT) in the trial group was lower than that in the control group, trial group was significantly higher than that in the control group.The rate of normal glu-cose tolerance in trial group was higher than that of control group, but the difference was not statistically significant ( P>0.05 ) .The incidence of adverse drug reactions in the trial group was 10.0%, which was signifi-cantly lower than that in the control group ( 22.5%, P <0.05 ) . Conclusion In elderly patients with coronary heart disease combined with reduced glucose resistance, the early intervention treatment effect using voglibose is ideal and the blood glucose and the incidence of cardiovascular disease of patients can be reduced.
